Checkpoint kinase inhibitor AZD7762 strongly sensitises urothelial carcinoma cells to gemcitabine

BACKGROUND: More effective chemotherapies are urgently needed for bladder cancer, a major cause of morbidity and mortality worldwide. We therefore explored the efficacy of the combination of gemcitabine and AZD7762, a checkpoint kinase 1/2 (CHK1/2) inhibitor, for bladder cancer. METHODS: Viability,...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:J Exp Clin Cancer Res
Main Authors: Isono, Makoto, Hoffmann, Michèle J., Pinkerneil, Maria, Sato, Akinori, Michaelis, Martin, Cinatl, Jindrich, Niegisch, Günter, Schulz, Wolfgang A.
Format: Artigo
Jezik:Inglês
Izdano: BioMed Central 2017
Teme:
Research
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC5209915/
https://ncbi.nlm.nih.gov/pubmed/28049532
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13046-016-0473-1
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki